{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:41:05Z","timestamp":1766504465974,"version":"3.33.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,6,15]],"date-time":"2007-06-15T00:00:00Z","timestamp":1181865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>Mesalazine (5\u2010ASA) is a standard treatment for ulcerative colitis. Extent of absorption and<jats:italic>N<\/jats:italic>\u2010acetylation determine systemic exposure to 5\u2010ASA, and are thereby relevant for the safety of the treatment. The aim of the study was to compare absorption and<jats:italic>N<\/jats:italic>\u2010acetylation of 5\u2010ASA following rectal or oral drug administration. Healthy subjects were compared to patients with ulcerative colitis to evaluate the impact of chronic inflammation of colorectal mucosa on disposition of 5\u2010ASA.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold>First, 12 healthy adults were randomized to receive 2 g of 5\u2010ASA by each of four different formulations: oral delayed release granules, 30\u00a0mL enema, 60\u00a0mL rectal foam, and 120\u00a0mL rectal foam. Second, 12 patients with active ulcerative colitis received 60\u00a0mL rectal foam. Pharmacokinetic analysis was performed by determination of 5\u2010ASA and its acetylated, pharmacologically inactive metabolite (Ac\u20105\u2010ASA) in plasma and urine.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>First, systemic exposure to 5\u2010ASA was markedly lower after rectal drug administration as compared to oral dosing (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b7001; e.g. median relative bioavailability of 60\u00a0mL rectal foam: 36%). Second,<jats:italic>N<\/jats:italic>\u2010acetylation of rectal 5\u2010ASA was lower in patients than in healthy subjects [area under the curve (AUC) ratio Ac\u20105\u2010ASA\/5\u2010ASA: 1\u00b76\u00a0\u00b1\u00a00\u00b75 vs. 2\u00b73\u00a0\u00b1\u00a00\u00b74, mean \u00b1 SD,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701]. High peak plasma concentrations of 5\u2010ASA were correlated with high microscopic disease activity (<jats:italic>r\u00a0=<\/jats:italic>\u00a00\u00b767,<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b705).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold>Rectal delivery of 5\u2010ASA results in low systemic drug exposure with potentially reduced toxicity in comparison with oral drug administration. Chronic inflammation of colorectal mucosa might be a relevant source of variability in pharmacokinetics of 5\u2010ASA.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2007.01809.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T13:32:08Z","timestamp":1182000728000},"page":"558-565","source":"Crossref","is-referenced-by-count":15,"title":["A clinical trial on absorption and<i>N<\/i>\u2010acetylation of oral and rectal mesalazine"],"prefix":"10.1111","volume":"37","author":[{"given":"K.","family":"Dilger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"R\u00f6ssle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Z\u00e4hringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Remmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Kreisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Novacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020831"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02846.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.410"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041948"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01308084"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb01944.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1988.tb00668.x"},{"key":"e_1_2_6_10_2","first-page":"2438","article-title":"Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease","volume":"125","author":"Netzer P","year":"1995","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0780105"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/03602530500251204"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/14.8.1633"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-100101932"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05838.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6666.82"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.174"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90621-4"},{"key":"e_1_2_6_19_2","first-page":"581","article-title":"Arylamine N\u2010acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity","volume":"57","author":"Cascorbi I","year":"1995","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_20_2","unstructured":"Guidance For Industry.Bioanalytical method validation. Food and Drug Administration. Available athttp:\/\/www.fda.gov\/cder\/guidance\/4252fnl.pdf."},{"volume-title":"Concepts and Applications","year":"1995","author":"Rowland M","key":"e_1_2_6_21_2"},{"key":"e_1_2_6_22_2","unstructured":"Note for guidance on the investigation of bioavailability and bioequivalence (CPMP\/EWP\/1401\/98). Available athttp:\/\/www.eudra.org\/emea\/html."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00269-5"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01409.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.4.400"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506010-00005"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001354"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000163"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0545"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199606000-00006"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.203"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.1.20"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO;2-L"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.04.019"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.29694"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0090-9556(24)15210-5","article-title":"Intestinal metabolism and transport of 5\u2010aminosalicylate","volume":"27","author":"Zhou SY","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0182-3"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2007.01809.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2007.01809.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:58:10Z","timestamp":1737100690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2007.01809.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1365-2362.2007.01809.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01809.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"type":"print","value":"0014-2972"},{"type":"electronic","value":"1365-2362"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}